Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty
{"title":"The role of melatonin and circadian rhythms in the pathogenesis of diabetic retinopathy: A systematic review","authors":"Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty","doi":"10.1016/j.dsx.2025.103202","DOIUrl":"10.1016/j.dsx.2025.103202","url":null,"abstract":"<div><h3>Aims</h3><div>This review investigates literature on systemic melatonin levels and circadian timing in diabetic retinopathy (DR), examining their associations with DR.</div></div><div><h3>Methods</h3><div>Our search was conducted in March 14, 2024, and included the databases Medline, Web of Science, Scopus, ProQuest Health, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane, International Standard Randomised Controlled Trial Number (ISRCTN) registry, and International Clinical Trials Registry Platform (ICTRP).</div></div><div><h3>Results</h3><div>Our review analysed twelve articles measuring melatonin concentration in saliva, blood serum, urine, or aqueous humour. Studies measuring melatonin levels in saliva found no significant differences in the average nocturnal or daytime melatonin levels between type 2 diabetes (T2D) patients with and without DR. The studies comparing serum melatonin levels in patients with different stages of DR and controls showed inconsistent results. Only two studies measured the endogenous onset of melatonin secretion, known as dim light melatonin onset (DLMO), a highly accurate biomarker for circadian regulation. These studies showed that only 33% and 57% of patients with DR had detectable DLMO in saliva and serum, respectively. All studies evaluating overnight melatonin production using urinary aMT6s (urinary 6-sulfaoxymelatonin) levels found that DR was associated with lower nocturnal melatonin production.</div></div><div><h3>Conclusions</h3><div>Our review results showed evidence of reduced nocturnal melatoin production in DR with no significant changes in melatonin circadian timing.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103202"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Agreement and disagreement between diagnostic criteria for gestational diabetes and implications for clinical practice: A retrospective observational study","authors":"Alpesh Goyal , Rahul Gupta , Avantika Gupta , Astha Yadav , Ashish Jadhav , Rekha Singh","doi":"10.1016/j.dsx.2025.103207","DOIUrl":"10.1016/j.dsx.2025.103207","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate agreement/disagreement between eleven gestational diabetes (GDM) diagnostic criteria, including five used in current clinical practice globally.</div></div><div><h3>Methods</h3><div>Records of 353 pregnant women with oral glucose tolerance test performed after 20 weeks of gestation were retrospectively reviewed. The diagnosis of GDM was compared using the IADPSG, DIPSI, WHO 1999, CDA 2003 and 2013, NICE 2015, JSOG 1984, ADIPS 1998, ADA 2004, NZSSD 2004 and EASD 1996 criteria. The agreement between criteria was expressed as Cohen's kappa coefficient (k; 0.4–0.6, moderate; 0.6–0.8, good; 0.8–1.0, very good) and disagreement as percentage (d). IADPSG criteria were used as a reference for comparison.</div></div><div><h3>Results</h3><div>The prevalence of GDM varied from 7.4 % (95 % CI, 4.9–10.4 %) by CDA 2003 criteria to 23.8 % (95 % CI, 19.5–28.4 %) by IADPSG criteria. Of the 55 pair-wise criteria comparisons, 29 (52.7 %) showed moderate, 16 (29.1 %) good, and 10 (18.2 %) very good agreement. Among the currently used criteria, the CDA 2013 (k = 0.811; d = 6.2 %) agreed the most, the DIPSI/WHO 1999 (k = 0.456) agreed the least, and the NICE 2015 (k = 0.580) criteria showed an intermediate agreement with the IADPSG criteria.</div></div><div><h3>Conclusions</h3><div>There is a marked variation in the prevalence of GDM, with a significant degree of disagreement between different diagnostic criteria. The study findings should be interpreted in the context of its retrospective nature and non-consecutive recruitment, which introduce a potential for selection bias.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103207"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan
{"title":"Ahmedabad declaration: A framework to combat growing epidemic of young-onset type 2 diabetes in Asia","authors":"Rakesh.M. Parikh , Banshi Saboo , Anoop Misra , Abdul Basit , S.R. Aravind , Bishwajit Bhowmik , Peter Schwarz , Ketan Dhatariya , Kamlesh Khunti , Shashank Joshi , Sunil Gupta , Amit Gupta , Manoj Chawla , Sanjeev Phatak , Sanjay Kalra , Azad Khan , Viswanathan Mohan","doi":"10.1016/j.dsx.2025.103205","DOIUrl":"10.1016/j.dsx.2025.103205","url":null,"abstract":"<div><h3>Aim</h3><div>Rising prevalence of Type 2 Diabetes (T2D) among young Asians has emerged as a public health crisis that threatens the long-term health, economic stability, and productivity of nations across Asia (1). Early-onset T2D poses unique challenges, including higher rates of undiagnosed cases, more aggressive disease progression, an increased risk of chronic complications and higher mortality (2). Hyperglycemia during the reproductive age especially among the female population can potentially have transgenerational impact through epigenetic changes.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted on PubMed with a combination of relevant keywords. A preliminary draft prepared after review of literature was electronically circulated among a panel of 64 experts from various parts of the region and representatives of the participating organizations - Diabetes India (<span><span>www.diabetesindia.org.in</span><svg><path></path></svg></span>) and the Diabetes Asia Study Group (DASG, <span><span>www.da-sg.org</span><svg><path></path></svg></span>).</div></div><div><h3>Results</h3><div>This Ahmedabad Declaration outlines the scale of the problem, its root causes, and a comprehensive action plan for Asian populations. The objectives of this declaration include raising awareness, addressing systemic barriers, and advocating for evidence-based policies and interventions, limited to people with T2D. Through collaborative efforts, we aim to mitigate the growing burden of diabetes in young Asians and secure a healthier future.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103205"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The effects of prune products consumption on anthropometric measurements and blood pressure in adults: A systematic review and dose-response meta-analysis","authors":"Azadeh Heydarian , Shima Moradi , Omid Asbaghi , Negin Tahvilian , Sahar Cheshmeh , Maryam Nadery , Naheed Aryaeian","doi":"10.1016/j.dsx.2024.103173","DOIUrl":"10.1016/j.dsx.2024.103173","url":null,"abstract":"<div><h3>Introduction</h3><div>The positive impact of prunes on body measurements and blood pressure has been suggested in previous research.</div></div><div><h3>Purpose</h3><div>The purpose of this extensive meta-analysis and systematic review was to examine the effects of adult consumption of prunes on anthropometric parameters and blood pressure.</div></div><div><h3>Methods</h3><div>To identify relevant randomized controlled trials (RCTs) (till August 9th, 2024), databases from ISI Web of Science, Scopus, and PubMed/Medline were searched. The current systematic review and meta-analysis covered 14 studies that met the eligibility requirements. The weighted mean difference was used to compute the effect size. The Cochrane Q test and I2 index were used to measure study heterogeneity. The random effects model was utilized to get the overall effect magnitude.</div></div><div><h3>Results</h3><div>The meta-findings analysis's showed that eating prunes had no appreciable effects on, body mass index (BMI) (p = 0.267), waist circumference (WC) (p = 0.562), fat mass (FM) (p = 0.840), systolic blood pressure (SBP) (p = 0.338), or diastolic blood pressure (DBP) (p = 0.233). However, we observed significantly reduction in body weight (p < 0.001) after prunes consumption.</div></div><div><h3>Conclusion</h3><div>Our findings showed that the consumption of prune leads to a significant reduction in body weight, but the results indicated non-significant effects on blood pressure, BMI, WC and FM.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103173"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ningjian Wang (Associate Editor) , Anoop Misra (Editor-in-Chief)
{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) , Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2025.103192","DOIUrl":"10.1016/j.dsx.2025.103192","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103192"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143170956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuming Sun , Qian zhou , Lorraine Edna Onzere , Yating Dian , Yu Meng , Daishi Li , Furong Zeng , Shaorong Lei , Guangtong Deng
{"title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","authors":"Yuming Sun , Qian zhou , Lorraine Edna Onzere , Yating Dian , Yu Meng , Daishi Li , Furong Zeng , Shaorong Lei , Guangtong Deng","doi":"10.1016/j.dsx.2025.103186","DOIUrl":"10.1016/j.dsx.2025.103186","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the causal association of using glucagon-like peptide-1 receptor (GLP1R) agonists with autoimmune diseases.</div></div><div><h3>Methods</h3><div>The available cis-eQTLs for drugs target genes (GLP1R) were used as genetic variants for exposure to GLP1R agonists. Type 2 diabetes was used as positive control. Mendelian randomizations (MR) were performed to explore the association of genetically-proxied GLP1R agonists with 11 autoimmune diseases from large-scale consortia. Replicating the findings in the FinnGen study and then pooled with meta-analysis. Finally, we performed MR analysis to examine whether GLP1R agonists affect 731 immune cell phenotypes to clarify the potential mechanism.</div></div><div><h3>Results</h3><div>We observed supportive evidence to support the association of GLP1R agonists with reduced the risk of hypothyroidism (OR [95 %] = 0.89 [0.82–0.95], <em>P</em> < 0.001), but increased risk of ulcerative colitis (OR [95 %] = 1.48 [1.27–1.71], <em>P</em> < 0.001), type 1 diabetes (OR [95 %] = 1.34 [1.21–1.50], <em>P</em> < 0.001), systemic lupus erythematosus (OR [95 %] = 1.61 [1.29–2.02], <em>P</em> < 0.001) and sarcoidosis (OR [95 %] = 1.38 [1.08–1.75], <em>P</em> = 0.008). There was no supporting evidence to verify the association of GLP1R expression with asthma, Crohn's disease, multiple sclerosis and myasthenia gravis (<em>P</em> > 0.05). In addition, we found that GLP1R agonists was positively associated with 221 immune cell phenotypes (P < 0.05, OR > 1), and negatively associated with 317 immune cell phenotypes (P < 0.05, OR < 1).</div></div><div><h3>Conclusion</h3><div>GLP1R agonists are causally associated with various autoimmune diseases potentially through the modulation of 731 immune cell phenotypes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103186"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The predictive value of estimated glucose disposal rate for all-cause and cardiovascular mortality in the US non-diabetic population aged ≥60 years: A population-based cohort study","authors":"Botao Zhu, Chenghui Cao, Wenwu Liu, Yuxuan Liu, Yonghong Luo, Daoquan Peng","doi":"10.1016/j.dsx.2024.103182","DOIUrl":"10.1016/j.dsx.2024.103182","url":null,"abstract":"<div><h3>Aims</h3><div>This study seeks to evaluate the prognostic significance of eGDR in predicting mortality outcomes within non-diabetic older adults.</div></div><div><h3>Methods</h3><div>8131 non-diabetic participants aged ≥60 years from the National Health and Nutrition Examination Survey (2001–2018) was included in this study. eGDR was calculated as: eGDR (mg/kg/min) = 21.158 – [0.09 × waist circumference (cm)] – [3.407 × Hypertension (Yes = 1/No = 0)] – [0.551 × HbA1c (%)]. Weighted Cox proportional hazards models, cumulative hazard curves, restricted cubic spline (RCS), and threshold effects analyses were performed to explore the relationship between eGDR and mortality outcomes. Subgroup analyses and mediation effects analyses were conducted.</div></div><div><h3>Results</h3><div>2566 all-cause deaths and 689 cardiovascular deaths were recorded. Lower eGDR was associated with higher all-cause (HR = 0.76, 95 % CI: 0.63–0.91) and cardiovascular mortality (HR = 0.56, 95 % CI: 0.40–0.80). Inflection points were identified through RCS curve analyses, and the threshold effect was significant. The eGDR-mortality association remained consistent across subgroups. Mediation analyses showed that neutrophil to high-density lipoprotein cholesterol ratio mediated the association.</div></div><div><h3>Conclusions</h3><div>Lower eGDR levels are linked to higher risk of both all-cause and cardiovascular mortality in non-diabetic older adults, suggesting its potential utility for risk assessment among this population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103182"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xin Chai , Yachen Wang , Xuejun Yin , Qiuhong Gong , Juan Zhang , Ruitai Shao , Guangwei Li
{"title":"Effects of lifestyle interventions on the prevention of type 2 diabetes and reversion to normoglycemia by prediabetes phenotype: A systematic review and meta-analysis of randomized controlled trials","authors":"Xin Chai , Yachen Wang , Xuejun Yin , Qiuhong Gong , Juan Zhang , Ruitai Shao , Guangwei Li","doi":"10.1016/j.dsx.2025.103184","DOIUrl":"10.1016/j.dsx.2025.103184","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the effects of lifestyle interventions on the prevention of type 2 diabetes (T2D) and reversion to normoglycemia by prediabetes phenotype.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) that evaluated the effects of lifestyle interventions in adults with prediabetes for a minimum duration of one year. Two reviewers independently screened articles, extracted data, and performed quality assessment. The relative effects were analyzed using a random-effects model, subgroup analysis was employed to explore the potential effects among subpopulations.</div></div><div><h3>Results</h3><div>A total of 31 RCTs involving 23684 participants were analyzed. Compared with usual care, lifestyle interventions reduced the incident T2D by 41 % (RR 0.59 [95 % CI 0.52–0.68]) and increased the probability of reverting to normoglycemia by 44 % (RR 1.44 [95 % CI 1.15–1.81]) in adults with prediabetes. No significant difference was observed between the impaired fasting glucose (IFG<sub>5.6</sub>)/impaired glucose tolerance (IGT) and IFG<sub>6.1</sub>/IGT (<em>P</em> = 0.752). IGT + IFG benefited more than isolated IGT in prevention of T2D (RR<sub>IGT + IFG</sub> 0.47 [95 % CI 0.41–0.55]; RR<sub>i</sub><sub>solated</sub> <sub>IGT</sub> 0.77 [95 % CI 0.64–0.93]), whereas no benefit was found in isolated IFG (RR 0.77 [95 % CI 0.51–1.16]) or elevated HbA1c (RR 0.89 [95 % CI 0.74–1.07]).</div></div><div><h3>Conclusions</h3><div>Lifestyle intervention could help prevent T2D and revert to normoglycemia in adults with prediabetes, with significant benefit in people with IGT but not in those with isolated IFG or elevated HbA1c.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103184"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anoop Misra , Naval K. Vikram , Amerta Ghosh , Piyush Ranjan , Seema Gulati , India Obesity Commission Members
{"title":"Revised definition of obesity in Asian Indians living in India","authors":"Anoop Misra , Naval K. Vikram , Amerta Ghosh , Piyush Ranjan , Seema Gulati , India Obesity Commission Members","doi":"10.1016/j.dsx.2024.102989","DOIUrl":"10.1016/j.dsx.2024.102989","url":null,"abstract":"<div><h3>Aim</h3><div>The prevailing guidelines for obesity in Asian Indians, published in 2009, relied solely on body mass index (BMI) criteria. Recognizing the limitations of BMI in accurately diagnosing obesity and the emergence of new research revealing the association between generalized and abdominal adiposity in Asian Indians and early-onset co-morbid diseases, a comprehensive redefinition was needed.</div></div><div><h3>Method</h3><div>In a Delphi process focused on obesity in India, experts were invited via email to participate in five rounds. The survey questions were administered through Google Form to gather insights from the selected experts.</div></div><div><h3>Results</h3><div>In Stage 1 Obesity, individuals exhibit increased adiposity (BMI>23 kg/m<sup>2</sup>) without discernible effects on organ functions or daily activities. Stage 2 Obesity denotes a more advanced state characterized by heightened adiposity (generalized and abdominal), impacting both physical and organ functions, resulting in functional limitations during day-to-day activities, and contributing to co-morbid diseases. The criteria for Stage 2 Obesity include a mandatory BMI exceeding 23 kg/m<sup>2</sup> and at least one of the following: excess waist circumference or waist-to-height ratio. Additionally, the presence of one or more symptoms indicative of limitations in daily activities or one or more obesity-related comorbid conditions/diseases are needed to support the stage 2 obesity.</div></div><div><h3>Conclusion</h3><div>This refined framework seeks to enhance precision in identifying obesity and its associated health risks among Asian Indians living in India, and facilitation of rational management, and aligns with worldwide initiative of new definition of obesity.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 102989"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The relevance of remnant cholesterol as a guide for lipid management in Indian subjects undergoing coronary revascularization","authors":"Manish Bansal , Ravi R. Kasliwal , Praveen Chandra , Rajneesh Kapoor , Nagendra Chouhan , Anil Bhan , Naresh Trehan","doi":"10.1016/j.dsx.2024.103183","DOIUrl":"10.1016/j.dsx.2024.103183","url":null,"abstract":"<div><h3>Background</h3><div>The atherogenic potential of remnant cholesterol, which refers to the cholesterol content of triglyceride-rich, non-low-density lipoprotein (LDL) particles in circulation, has gained increasing attention recently. Unfortunately, very limited information is available regarding remnant cholesterol levels in Indian subjects.</div></div><div><h3>Methods</h3><div>This was a retrospective study conducted at a premier, tertiary care center in North India. A total of 3064 consecutive subjects [mean age 61.3 ± 10.3 years, 2550 (83.2%) men] with newly diagnosed coronary artery disease (CAD) undergoing coronary revascularization were included. Enzymatic assays were used for measuring various lipid parameters. Remnant cholesterol was calculated by subtracting LDL cholesterol (LDL-C) and high-density lipoprotein cholesterol from total cholesterol. A value >30 mg/dL was considered elevated.</div></div><div><h3>Results</h3><div>The mean LDL-C was 79.1 ± 33.1 mg/dL with 46.4% of all subjects having LDL-C <70 mg/dL and only 16.9% having LDL-C <50 mg/dL. The median remnant cholesterol level was 17.0 mg/dL (interquartile range 12.0–24.0 mg/dL) with only 11.9% of subjects having values >30 mg/dL. Only 4.5% of the patients with LDL-C <70 mg/dL and 2.9% of those with LDL-C <50 mg/dL had elevated remnant cholesterol. These proportions were significantly greater in patients with serum triglycerides >200 mg/dL.</div></div><div><h3>Conclusion</h3><div>Our study shows that in a North-Indian population with CAD, elevated remnant cholesterol was present in only a small proportion. The prevalence of elevated remnant cholesterol decreased further as the LDL-C control improved. These findings suggest that elevated remnant cholesterol may not be a clinically relevant therapeutic target in most patients with LDL-C below the currently recommended goals.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 1","pages":"Article 103183"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}